CATALYST PHARMACEUTICALS, INC. (CPRX) research
CATALYST PHARMACEUTICALS, INC.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $31.49
- As of
CATALYST PHARMACEUTICALS, INC. (CPRX): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-07-16.
As of . Source: SEC EDGAR filings for CPRX. Method and limitations.
Share the CPRX intelligence card
See CPRX live in the terminal
Track CPRX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live CPRX terminal, freeActive signals for CPRX
- highCONSENSUS_BUY
3 tracked funds increased CPRX this 2026Q2, institutional consensus
- highCONSENSUS_BUY
5 tracked funds increased CPRX this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 59% of CPRX (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +5244% to CPRX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +634% to CPRX (2026Q2)
FREE, NO ACCOUNT
Every signal on CPRX, as it fires
You are seeing 5 of 33 signals recorded on CPRX since 2026-05-31.
The five above landed across 2 days. The other 28 were recorded on 3 other days. 25 of the 33 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CPRX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 14888U101 · 2026Q2 | $67.1M | 0.09% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 14888U101 · 2026Q2 | $33.6M | 0.01% | , |
| SOROS FUND MANAGEMENT LLCCUSIP 14888U101 · 2026Q2 | $10.8M | 0.13% | , |
| Point72 Asset Management, L.P.CUSIP 14888U101 · 2026Q2 | $5.5M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 14888U101 · 2026Q2 | $4.2M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 14888U101 · 2026Q2 | $2.7M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 14888U101 · 2026Q2 | $954K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CPRX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CPRX against its peers
CPRX's operating margin of 43.8% ranks in the 96th percentile of 13 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | CPRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 589M USD | 147M USD | 78 | 15 |
| Operating margin | 43.8% | -153.1% | 96 | 13 |
| Net margin | 36.4% | -148.4% | 89 | 13 |
| Return on equity | 22.5% | -30.9% | 89 | 22 |
Peers (23): ELVN, CELC, TNGX, IDYA, GRAL, RLAY, LEGN, TLX, GRTX, VKTX, DYN, MANE, IOVA, DNLI, VCYT, RCUS, ACAD, EWTX, DFTX, CLDX, QURE, MBX, ARQT. Left out: PBLS (no annual filing), ZLDPF (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (CPRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more CPRX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CPRXand get the insider, 13F, options, and confluence read in one view.